Telswit‑H Tablets provide a synergistic combination of Telmisartan 40 mg, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide 12.5 mg, a thiazide diuretic. This fixed-dose formulation is designed to effectively lower blood pressure in patients not adequately controlled by monotherapy.
🔹 Mechanism:
-
Telmisartan blocks angiotensin II effects, causing vasodilation and sodium retention reduction.
-
Hydrochlorothiazide increases urinary sodium and water excretion, helping reduce blood volume and cardiac workload.
🔹 Clinical Benefits:
-
Enhanced antihypertensive efficacy due to complementary mechanisms
-
Lower risk of fluid retention, improved metabolic profile
-
Once-daily dosing improves adherence
🔹 Indications:
-
Essential hypertension unresponsive to single agent therapy
-
Cardiovascular risk reduction in hypertensive individuals
🔹 Dosage:
One tablet daily, preferably in the morning. Monitor blood pressure and electrolytes periodically.
🔹 Safety & Precautions:
-
Monitor renal function and potassium levels
-
Use caution in patients with gout, diabetes, or electrolyte imbalance
-
Avoid during pregnancy and lactation
-
May cause dizziness, thirst, or leg cramps
🔹 Storage:
Store in airtight blister packs below 25 °C, away from moisture and light.
Telswit‑H delivers a potent antihypertensive combination to optimize blood pressure control and reduce cardiovascular risk.
